Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Gross Margin (2018 - 2026)

Sunshine Biopharma filings provide 8 years of Gross Margin readings, the most recent being 35.31% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 308.0% to 35.31% in Q4 2025 year-over-year; TTM through Dec 2025 was 33.76%, a 316.0% increase, with the full-year FY2025 number at 33.76%, up 316.0% from a year prior.
  • Gross Margin hit 35.31% in Q4 2025 for Sunshine Biopharma, up from 32.64% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 64.98% in Q2 2021 to a low of 25.33% in Q2 2024.
  • Median Gross Margin over the past 5 years was 35.21% (2023), compared with a mean of 39.75%.
  • Biggest five-year swings in Gross Margin: plummeted -3465bps in 2021 and later surged 1105bps in 2025.
  • Sunshine Biopharma's Gross Margin stood at 28.0% in 2021, then skyrocketed by 35bps to 37.85% in 2022, then dropped by -12bps to 33.44% in 2023, then dropped by -4bps to 32.24% in 2024, then increased by 10bps to 35.31% in 2025.
  • The last three reported values for Gross Margin were 35.31% (Q4 2025), 32.64% (Q3 2025), and 36.37% (Q2 2025) per Business Quant data.